Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512930 | 1.00 | CNR2 (0.41) | CNR2PIK3CAPRKDCMRGPRX1IDH1 | |
| SCHEMBL21513479 | 0.88 | PRKDC (0.44) | CNR2PIK3CAPRKDC | |
| SCHEMBL29661229 | 0.88 | PRKDC (0.44) | CNR2PIK3CAPRKDC | |
| SCHEMBL29629172 | 0.84 | PRKDC (0.38) | CNR2PRKDC | |
| SCHEMBL21512929 | 0.84 | CNR2 (0.39) | CNR2PRKDCTSPOBRD4 | |
| SCHEMBL21513802 | 0.84 | PRKDC (0.38) | CNR2PRKDC | |
| SCHEMBL3120337 | 0.82 | MRGPRX1 (0.45) | CNR2PIK3CAMRGPRX1TSPOMTOR | |
| SCHEMBL21513803 | 0.82 | PRKDC (0.37) | CNR2PRKDC | |
| SCHEMBL21513800 | 0.82 | PRKDC (0.37) | CNR2PRKDC | |
| SCHEMBL29969548 | 0.82 | PRKDC (0.37) | CNR2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | CNR2 4823/4885PIK3CA 480/4885PRKDC 57/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | CNR2 4823/4885PIK3CA 480/4885PRKDC 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.